Overall evaluation of immunomodulators.
Revillard
J P
JP
INSERM, Lyon.
Sizaret
P
P
D000276:Adjuvants, Immunologic / Q000145:classification / Q000494:pharmacology / Q000592:standards / Q000627:therapeutic use; D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods; D004195:Disease Models, Animal; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000628:therapy; D007155:Immunologic Factors / Q000627:therapeutic use; D008070:Lipopolysaccharides / Q000737:chemistry; D008213:Lymphocyte Activation / Q000187:drug effects; D008262:Macrophage Activation / Q000187:drug effects; D009369:Neoplasms / Q000628:therapy; D011786:Quality Control; D013329:Structure-Activity Relationship
D000276:Adjuvants, Immunologic; D007155:Immunologic Factors; D008070:Lipopolysaccharides